Clinical picture, diagnosis and treatment of chlamydia pneumonia;Klinisches bild, diagnostik und therapie der chlamydien-pneumonie

Pneumologie

Volumn 57, Issue 8, 2003, Pages 449-458

  Burkhardt, O ^a   Straube, E ^b   Welte, T ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; KETOLIDE; LEVOFLOXACIN; MACROLIDE; MINOCYCLINE; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; SPARFLOXACIN; STREPTOGRAMIN; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; TROVAFLOXACIN;

ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL FEATURE; DIAGNOSTIC TEST; ELECTROIMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INCIDENCE; PRIORITY JOURNAL; REVIEW;

ANTI-BACTERIAL AGENTS; CHLAMYDIA INFECTIONS; HUMANS; INCIDENCE; PNEUMONIA, BACTERIAL;

EID: 0041857735     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-41550     Document Type: Review

References (114)

1. Fang G, Fine M, Orloff J et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 356 cases. Medicine 1990; 69: 307-316
2. Mandall LA. Comunity-acquired pneumonia: etiology, epidemiology, and treatment. Chest 1995; (suppl) 108: 35-42
3. Lode H, Steinhoff D, Schaberg T et al. New pneumonia pathogens, especially Chlamydia pneumoniae and Hantaviruses. Internist (Berl) 1996; 37: 882-889
4. Steinhoff D, Lode H, Ruckdeschel G et al. Chlamydia pneumoniae as a cause of community-acquired pneumonia is hospitalised patients in Berlin. Clin Infect Dis 1996; 22: 958-964
5. Allewelt M, Steinhoff D, Rahlwes M et al. Wandel im Erregerspektrum ambulant erworbener Pneumonien (1982-1992). Dtsch Med Wschr 1997; 122: 1027-1032
6. Plouffe JF. Importance of atypical pathogens of community-acquired pneumonia. Clin Infect Dis 2000; (suppl) 31: 35-39
7. Cosentini R, Tarsia P, Blasi F et al. Community-acquired pneumonia: role of atypical organisms. Monalde Arch Chest Dis 2001; 56: 527-534
8. Gupta SK, Sarosi GA. The role of atypical pathogens in community-acquired pneumonia. Med Clin North Am 2001; 85: 1349-1365
9. Marrie TJ. Community-acquired pneumonia. Clin Infect Dis 1994; 18: 501-515
10. Bartlett JG, Mundy LM. Community-acquired pneumonia. New Engl J Med 1995; 333: 1618-1624
11. Kauppinen MT, Saikku P, Kujala P et al. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. Thorax 1996; 51: 185-189
12. Lieberman D, Schlaeffer F, Boldur I et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996; 51: 179-184
13. Lieberman D, Ben-Yaakov M, Lazarovich Z et al. Chlamydia pneumoniae community-acquired pneumonia: a review of 62 hospitalized adult patients. Infection 1996; 24: 109-114
14. Dowell SF, Peeling RW, Boman J et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infec Dis 2001; 33: 492-503
15. Kuo CC, Jackson LA, Campbell LA et al. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev 1995; 8: 451-461
16. Schachter J, Stamm WE. Chlamydia. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. Washington, D.C.: 7th ed. Press, 1999: 669-677
17. Stephens RS(ed). Chlamydia: intracellular biology, pathogenesis, and immunity. Washington, D.C.: American Society for Microbiology, 1999
18. Everett KDE, Bush RM, Andersen AA. Emended description of the order Chlamydiales, proposal of Parachlamydiaceae fam. Nov. and Simkaniaceae fam. Nov., each containing one monotypic genus, revised taxonomy of the family Chlamydiaceae, including a new genus and five new species, and standards for the identifications of organisms. Int J Syst Bactiriol 1999; 49: 415-440
19. Amann R, Springer N, Schönhuber W et al. Obligate intracellular bacterial parasites of acanthamoebae related to Chlamydia spp. Appl Environ Microbiol 1997; 63: 115-121
20. Fritsche TR, Horn M, Wagner M et al. Phylogenetic diversity among geographically dispersed Chlamydiales endosymbionts recovered from clinical and environmental isolates of Acanthamoeba spp. Appl Environ Microbiol 2000; 66: 2613-2619
21. Horn M, Wagner M, Müller KD et al. Neochlamydia hartmannellae gen. nov., sp. nov. (Parachlamydiaceae), an endoparasite of the amoeba Hartmanellae vermiformis. Microbiology 2000; 146: 1231-1239
22. Kahane S, Everett KD, Kimmel N et al. Simkania negevensis strain ZT: growth, antigenic and genome characteristics. Int J Syst Bacteriol 1999; 49: 815-820
23. Grayston JT, Diwan VK, Cooney M et al. Community- and hospital-acquired pneumonia associated with Chlamydia TWAR infection demonstrated serologically. Arch Intern Med 1989; 149: 169-173
24. Grayston JT, Campbell LA, Kuo CC et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990; 161: 618-625
25. Chirgwin K, Roblin PM, Gelling M et al. Infection with Chlamydia pneumoniae in Brooklyn. J Infect Dis 1991; 163: 757-761
26. Kauppinen M, Saikku P. Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis, and treatment. Clin Inf Dis 1995; (suppl) 3: 244-252
27. Suttithawil W, Wangroongsarb P, Naigowit P et al. Chlamydia (Chlamydia) pneumoniae as a cause of community-acquired pneumonia in Thailand. J Med Assoc Thai 2001; 84: 430-437
28. Kese D, Cizman M, Marin J et al. Chlamydia pneumoniae infections in patients with community-acquired pneumonia in Slovenia. Scand J Inf Dis 2002; 34: 172-176
29. Miyashita N, Fukano H, Okimoto N et al. Clinical presentation of community-acquired pneumonia in adults. Chest 2002; 121: 1776-1781
30. Hammerschlag MR. Chlamydia pneumoniae and the lung. Eur Respir J 2000; 16: 1001-1007
31. Beaty CD, Grayston JC, Wang SP et al. Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 144: 1408-1410
32. Karnak D, Beder S. Treatment of Chlamydia pneumoniae infection and chronic obstructive pulmonary disease. Expert Opin Pharmacother 2002; 3: 1461-1470
33. Kraft M. The role of bacterial infections in asthma. Clin Chest Med 2000; 21: 301-313
34. Hertzen L von. Role of persitent infection in the control and severity of asthma: focus on Chlamydia pneumoniae. Eur Respir J 2001; 19: 546-556
35. Wong YK, Gallagher PJ, Ward ME. Chlamydia pneumoniae and atherosclerosis. Heart 1999; 81: 232-238
36. Campball LA, Kuo CC. Chlamydia pneumoniae pathogenesis. J Med Microbiol 2002; 51: 623-625
37. Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular diseases. JAMA 2002; 288: 2724-2731
38. Ngeh J, Anand V, Gupta S. Chlamydia pneumoniae and atherosklerosis - what we know and what we don't. Clin Microbiol Infect 2002; 8: 2-13
39. Balin BJ, Appelt DM. Role of infection in Alzheimer' disease. J Am Osteopath Assoc 2001; (suppl) 12: 1-6
40. Yucesan C, Sriram S. Chlamydia pneumoniae infection of the central nervous system. Curr Opin Neurol 2001; 14: 355-359
41. Saikku P, Wang SP, Kleemola M et al. An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci. J Infect Dis 1985; 151: 832-839
42. Storey C, Lusher M, Yates P et al. Evidence for Chlamydia pneumoniae of non-human origin. J Gen Bacteriol 1993; 139: 2621-2626
43. Forsey T, Darougar S, Treharne JD. Prevalence in human beings of antibodies to Chlamydia IOL-207, an atypical strain of chlamydia. J Infect 1986; 12: 145-152
44. Kanamoto Y, Ouchi K, Mizui M et al. Prevalence of antibody to Chlamydia pneumoniae TWAR in Japan. J Clin Microbiol 1991; 29: 816-818
45. Marton A, Karolyi A, Szalka A. Prevalence of Chlamydia pneumoniae antibodies in Hungary. Eur J Clin Microbiol Infect Dis 1992; 11: 139-142
46. Montes M, Cilia G. High prevalence of Chlamydia pneumoniae infection in children and young adults in Spain. Pediatr Infect Dis J 1992; 11: 972-973
47. Grayston JT. Infections caused by Chlamydia pneumoniae strain TWAR. Clin Inf Dis 1992; 15: 757-763
48. Grayston JT, Diwan VK, Cooney M et al. Community- and hospital-acquired pneumonia associated with Chlamydia TWAR infection demonstrated serologically. Arch Intern Med 1989; 149: 169-173
49. Cosentini R, Blasi F, Rossi S et al. Chlamydia pneumoniae and severe community-acquired pneumonia. In: Orfila J, Byrne GI, Cherneskey MA, Grayston JT, et al. eds. Chlamydial infections - 1994. Bologna, Italy: Societa Editrice Esculapio, 1994: 453-456
50. Gaydos CA, Eiden JJ, Oldach D et al. Diagnosis of Chlamydia pneumoniae in patients with community-acquired pneumonia by polymerase chain reaction enzyme immunoassay. Clin Infect Dis 1994; 19: 157-160
51. Kauppinen M, Kujala P, Leinonen M et al. Clinical features of community-acquired Chlamydia pneumoniae pneumonia. In: Orfila J, Byrne GI, Cherneskey MA, et al. eds. Chlamydial infections - 1994. Bologna, Italy: Societa Editrice Esculapio, 1994: 457-460
52. Wainwright AP, Beaumont AC, Kox WJ. Psittacosis: diagnosis and management of severe pneumonia and multi organ failure. Intensive Care Med 1987; 13: 419-421
53. Gregory DW, Schaffner W. Psittacosis. Semin Respir Infect 1997; 12: 7-11
54. Elliott JH. Psittacosis. A flu like syndrome. Aust Fam Physician 2001; 30: 739-741
55. Cles LD, Stamm WE. Use of HL cells for improved isolation and passage of Chlamydia pneumoniae. J Clin Microbiol 1990; 28: 938-940
56. Kuo CC, Grayston JT. A sensitive cell line, HL cells, for isolation and propagation of Chlamydia pneumoniae strain TWAR. J Inf Dis 1990; 162: 755-758
57. Wong KH, Skelton SK, Chan YK. Efficient culture of chlamydia pneumoniae with cell lines derived from the human respiratory tract. J Clin Microbiol 1992; 30: 1625-1630
58. Grayston JT, Kuo CC, Wang SP et al. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infection. N Engl J Med 1986; 315: 161-168
59. Kuo CC, Chen HH, Wang SP et al. Identification of a new group of Chlamydia psittaci strains called TWAR. J Clin Microbiol 1986; 24: 1034-1037
60. Person K, Haidl S. Evaluation of a commercial test for antibodies to the chlamydial lipopolysaccharide (Medac) for serodiagnosis of acute infections by Chlamydia pneumoniae (TWAR) and Chlamydia psittaci. APMIS 2000; 108: 131-138
61. Johnsen S, Andersen PL, Stanek G et al. Chlamydia antibody response in healthy volunteers immunized with nonchlamydial antigens: a randomized, double-blind, placebo-controlled study. Clin Inf Dis 2003; 36: 586-591
62. Nurminen M, Leinonen M, Saikku P et al. The genus-specific antigen of Chlamydia: resemblance to the lipopolysaccharide of enteric bacteria. Science 1983; 220: 1279-1281
63. Peeling R. Chlamydia pneumoniae infections: applications of laboratory methods. In: Allegra L, Blasi F, eds. Chlamydia pneumoniae: the lung and the heart. Milano: Springer-Verlag Italia, 1999: 33-42
64. Wang S. Serology for Chlamydia pneumoniae (TWAR). In: Allegra L, Blasi F, eds. Chlamydia pneumoniae: the lung and the heart. Milano: Springer-Verlag Italia, 1999: 16-23
65. Wang SP, Grayston JT. Immunologic relationship between genital TRIC, lymphogranuloma venereum, and related organisms in a new microtiter indirect immunofluorescence test. Am J Ophthal 1970; 70: 367-374
66. Schachter J. Chlamydiae. In: Rose NR, DeMarcario EC, Fahey JL, Friedman H, Pen GM, eds. Manual of clinical laboratory immunology. Washington, D.C.: 4th ed. American Society for Microbiology, 1992: 661-666
67. Ekman MR, Leinonen M, Syrjala H et al. Evaluation of serological methods in the diagnosis of Chlamydia pneumoniae pneumonia during an epidemic in Finland. Eur J Clin Microbiol Infect Dis 1993; 12: 756-760
68. Verkooyen RP, Lent NA van, Mousavi Joulandan SA et al. Diagnosis of Chlamydia pneumoniae in fection in patients with chronic obstructive pulmonary diseases by microimmunofluorescence and ELISA. J Med Microbiol 1997; 46: 959-964
69. Verkooyen RP, Willemse D, Hiep-van Casteren SCAM et al. Evaluation of PCR, culture, and serology for diagnosis of Chlamydia pneumoniae respiratory infections. J Clin Microbiol 1998; 36: 2301-2307
70. Peeling RW, Wang SP, Grayston JT et al. Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results. J Inf Dis 2000; (suppl) 181: 426-429
71. Messmer TO, Martinez J, Hassouna F et al. Comparison of two commercial microimmunofluorescence kits for detection of serum immunoglobulin G antibodies to Chlamydia pneumoniae. Clin Diagn Lab Immunol 2001; 8: 588-592
72. Hermann C, Graf K, Groh A et al. Comparison of eleven commercial tests for Chlamydia pneumoniae-specific immunoglobulin G in asymptomatic healthy individuals. J Clin Microbiol 2002; 40: 1603-1609
73. Tugwell P, Dennis DT, Weinstein A et al. Laboratory evaluation in the diagnosis of Lyme disease. Ann Intern Med 1997; 127: 1109-1123
74. Bas S, Muzzin P, Ninet B et al. Chlamydial serology: comparative diagnostic value of immunoblotting, microimmunofluorescence test, and immunoassays using different recombinant proteins as antigens. J Clin Microbiol 2001; 39: 1368-1377
75. Boman J, Allard A, Persson K et al. Rapid diagnosis of respiratory Chlamydia pneumoniae infection by nested touchdown polymerase chain reaction compared with culture and antigen detection by EIA. J Infect Dis 1997; 175: 1523-1526
76. Tong C, Sillis M. Detection of Chlamydia pneumoniae and Chlamydia psittaci in sputum samples by PCR. J Clin Pathol 1993; 46: 313-317
77. Campbell LA, Melgosa MP, Hamilton DJ et al. Detection of Chlamydia pneumoniae by polymerase chain reaction. J Clin Microbiol 1992; 30: 434-439
78. Gaydos CA, Roblin PM, Hammerschlag MR et al. Diagnostic utility of PCR-enzyme immunoassay, culture and serology for detection of Chlamydia pneumoniae in symptomatic and asymptomatic patients. J Clin Microbiol 1994; 32: 903-905
79. Hyman CL, Roblin PM, Gaydos CA et al. Prevalence of asymptomatic nasopharyngeal carriage of Chlamydia pneumoniae in subjectively healthy adults: assessment by polymerase chain reaction-enzyme immunoassay and culture. Clin Infect Dis 1995; 20: 1174-1178
80. Mygind T, Birkelund S, Birkebaek N et al. Determination of PCR efficiency in chelex-100 purified clinic samples and comparison of real-time quantitative PCR and conventional PCR for detection of Chlamydia pneumoniae. BMC Microbiol 2002; 9: 17
81. Tondella ML, Talkington DF, Holloway BP et al. Development and evaluation of real-time PCR-based fluorescence assays for detection of Chlamydia pneumoniae. J Clin Microbiol 2002; 40: 575-583
82. Kuoppa Y, Boman J, Scott L et al. Quantitative detection of respiratory Chlamydia pneumoniae infection by real-time PCR. J Clin Microbiol 2002; 40: 2273-2274
83. Apfalter P, Barousch W, Nehr M et al. Comparison of a new quantitative ompA-based real-time PCR TaqMan assay for detection of Chlamydia pneumoniae DNA in respiratory specimens with four conventional PCR assays. J Clin Microbiol 2003; 41: 592-600
84. Reischl U, Lehne N, Simnacher U et al. Rapid and standized detection of Chlamydia pneumoniae using LightCycler real-time fluorescence PCR. Eur J Clin Microbiol Infect Dis 2003; 22: 54-57
85. Welti M, Jaton K, Altwegg M et al. Development of a multiplex real-time quantitative PCR assay to detect Chlamydia pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae in respiratory tract secretions. Diagn Microbiol Infect Dis 2003; 45: 85-95
86. Poppert S, Essig A, Marre R et al. Detection and differentiation of Chlamydiae by fluorescence in situ hybridization. Appl Environ Microbiol 2002; 68: 4081-4089
87. Niedermann MS, Mandell LA, Anzueto A et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, initial antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 148: 1730-1754
88. Schaberg T, Dalhoff K, Ewig S et al. Deutsche Gesellschaft für Pneumologie. Empfehlungen zur Therapie der ambulant erworbenen Pneumonie. Pneumologie 1998; 51: 450-462
89. Bartlett JG, Dowell FS, Mandell LA et al. Practice guidelines for the management of community acquired pneumonia in adults. Clin Inf Dis 2000; 31: 347-382
90. Mandall LA, Marrie TJ, Grossman RF et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000; 31: 383-421
91. Hammerschlag MR. Antimicrobial susceptibility and therapy of infections caused Chlamydia pneumoniae. Antimicrob Agents Chemother 1994; 38: 1873-1878
92. Roblin PM, Kutlin A, Hammerschlag MR. In vitro activity of trovafloxacin against Chlamydia pneumoniae. Antimicrob Agents Chemother 1997; 41: 2033-2034
93. Roblin PM, Hammerschlag MR. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. Antimicrob Agents Chemother 1998; 42: 951-952
94. Hammerschlag MR, Qumei KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, L-ofloxacin and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992; 36: 1573-1574
95. Ridgway GL, Salman H, Robbins MJ et al. In-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. J Antimicrob Chemother 1997; (suppl) 40: 31-34
96. Miyashita N, Niki Y, Kishimoto T et al. In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Antimicrob Agents Chemother 1997; 41: 1331-1334
97. Donati M, Rodriguez Fermepin M, Olmo A et al. Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp. J Antimicrob Chemother 1999; 43: 825-827
98. Kimura M, Kishimoto T, Niki Y et al. In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents. Antimicrob Agents Chemother 1993; 37: 801-803
99. Roblin PM, Kutlin A, Reznik T et al. Activity of grepafloxacin and other fluoroquinolones and newer macrolides against recent clinical isolates of Chlamydia pneumoniae. Int J Antimicrob Agents 1999; 12: 181-184
100. Roblin PM, Hammerschlag MR. In vitro activity of Gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae. J Antimicrob Chemother 1999; 44: 549-551
101. Roblin PM, Reznik T, Kutlin A et al. In vitro activities of gemifloxacin (SB-265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother 1999; 43: 2806-2807
102. Block S, Hedrick J, Hammerschlag MR et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia; comparative efficacy and safety of clarithromycin vs erythromycin ethylsuccinate. Pediatr Infect Dis J 1995; 14: 471-477
103. Roblin PM, Hammerschlag MR. Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired peumonia. Antimicrob Agents Chemother 1998; 42: 194-196
104. Balfour JA, Figgitt DP. Telithromycin. Drugs 2001; 61: 815-829
105. Roblin PM, Hammerschlag MR. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob Agents Chemother 1998; 42: 1515-1516
106. Strigl S, Robin PM, Reznik T et al. In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae. Antimicrob Agents Chemother 2000; 44: 1112-1113
107. Dessus-Babus S, Bebear CM, Charron A et al. Sequencing of gyrase and topoisomerase IV quinolone-resistence-determining regions of Chlamydia trachomatis and characterization of quinolon-resistent mutants obtained in vitro. Antimicrob Agents Chemother 1998; 42: 1474-2481
108. Hammerschlag MR. Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: a review. J Antimicrob Chemother 2000; (suppl) 45: 35-39
109. Hammerschlag MR, Hyman CL, Roblin PM. In vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992; 36: 682-683
110. Woodcock JM, Andrews JM, Boswell FJ et al. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997; 41: 101-106
111. Wise R, Andrews JM, Brenwald N. The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone. J Antimicrob Chemother 1993; 31: 497-504
112. Roblin PM, Montalban G, Hammerschlag MR. In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae. Antimicrob Agents Chemother 1994; 38: 1402-1403
113. Plouffe JF, Herbert MT, File jr TM et al. Ofloxacin versus standard therapy in treatment of community-acqired pneumonia requiring hospitalization. Pneumonia Study Group. Antimicrob Agents Chemother 1996; 40: 1175-1179
114. File jr TM, Segreti J, Dunbar L et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41: 1965-1972